Afficher la notice abrégée

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

dc.rights.licenseopenen_US
dc.contributor.authorLADOUCEUR, Alexandra
dc.contributor.authorBARNETCHE, Thomas
dc.contributor.authorMOUTERDE, G.
dc.contributor.authorTISON, A.
dc.contributor.authorBITOUN, S.
dc.contributor.authorPREY, Sorilla
dc.contributor.authorDUTRIAUX, Caroline
dc.contributor.authorGERARD, Emilie
dc.contributor.authorPHAM-LEDARD, Anne
dc.contributor.authorBEYLOT-BARRY, Marie
dc.contributor.authorZYSMAN, Maeva
dc.contributor.authorVEILLON, Remi
dc.contributor.authorDOMBLIDES, Charlotte
dc.contributor.authorDASTE, A.
dc.contributor.authorGROSS-GOUPIL, M.
dc.contributor.authorSIONNEAU, B.
dc.contributor.authorLEFORT, F.
dc.contributor.authorLARROQUETTE, M.
hal.structure.identifierImmunology from Concept and Experiments to Translation [ImmunoConcept]
dc.contributor.authorRICHEZ, Christophe
dc.contributor.authorTRUCHETET, M.-E.
dc.contributor.authorSCHAEVERBEKE, T.
dc.contributor.authorKOSTINE, M.
dc.date.accessioned2024-05-03T07:05:34Z
dc.date.available2024-05-03T07:05:34Z
dc.date.issued2023
dc.identifier.issn2056-5933en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199580
dc.description.abstractEnObjective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to assess the rate and clinical features associated with ICI-IA flare/recurrence on ICI rechallenge. Methods We conducted a multicentre observational study including cancer patients with ICI-IA who started a second course of ICI more than 3 months after ICI discontinuation in four French university hospitals. Primary outcome was the frequency of ICI flare/recurrence after ICI rechallenge. Results Twenty-three patients were included. At the time of ICI rechallenge, 18 patients reported no symptoms of ICI-IA (78%) and 5 had grade 1 (22%), 11 patients (48%) were not receiving any ICI-IA treatment, 11 (48%) were still on prednisone, 2 (9%) were on conventional synthetic disease-modifying antirheumatic drugs and 1 (4%) on anti-IL-6. ICI-IA flare/recurrence occurred in 12 patients (52%) with a median time of 1 month after ICI rechallenge. ICI-IA phenotype, disease activity and ICI-IA treatment at the time of ICI rechallenge did not differ according to ICI-IA flare/ recurrence status. Conclusion In this first observational study of ICI-IA patients rechallenged with ICI, about half of the patients experienced ICI-IA flare/recurrence with a similar phenotype but occurring earlier than the initial ICI-IA, warranting close monitoring during the first month of retreatment. Risk of flare did not differ according to baseline immunosuppressive treatment at the time of rechallenge. © Author(s) (or their employer(s)) 2023.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subject.enAntirheumatic Agents; Arthritis
dc.subject.enGlucocorticoids
dc.subject.enOutcome Assessment
dc.subject.enHealth Care
dc.subject.enRisk Factors
dc.title.enImmune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/rmdopen-2023-003795en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed38030233en_US
bordeaux.journalRMD Openen_US
bordeaux.volume9en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04567146
hal.version1
hal.date.transferred2024-05-03T07:05:38Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccCC BY-NCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD%20Open&rft.date=2023&rft.volume=9&rft.issue=4&rft.eissn=2056-5933&rft.issn=2056-5933&rft.au=LADOUCEUR,%20Alexandra&BARNETCHE,%20Thomas&MOUTERDE,%20G.&TISON,%20A.&BITOUN,%20S.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
ImmunoConcept_RMD_Open_2023_La ...
Taille:
429.5Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
920octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée